Ocular Therapeutix (OCUL) EBIT Margin (2014 - 2026)
Ocular Therapeutix (OCUL) posted quarterly EBIT Margin of 609.34% for Q2 2026, down 10677.0% year-over-year from N/an in Q2 2025, and up 29.59% on a QoQ basis from 865.46% in Q1 2026.
Powered by 
Analysis
Ocular Therapeutix (OCUL) EBIT Margin (2014 - 2026) Analysis & Trends
Ocular Therapeutix has reported EBIT Margin for 13 years, with the latest figure at 609.34% in Q2 2026.
- EBIT Margin for Q2 2026 came in at 609.34%, down 10677.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 603.04% (down 20044.0% YoY), and the FY2025 annual result was 519.75%, down 25018.0% from the prior year.
- EBIT Margin climbed to 609.34% in Q2 2026, from 865.46% in the prior quarter.
- Over five years, EBIT Margin peaked at 127.41% in Q3 2023 and troughed at 865.46% in Q1 2026.
- A 5-year average of 323.85% and a median of 239.57% in 2024 frame the typical range for EBIT Margin.
- The widest annual swing landed in 2022, when EBIT Margin jumped 14028 bps; it then plunged 38346 bps in 2025.
- A 5-year view of EBIT Margin shows it stood at 137.56% in 2022, then climbed by 2 bps to 135.46% in 2023, then plunged by 119 bps to 296.08% in 2024, then plunged by 78 bps to 526.49% in 2025, then dropped by 16 bps to 609.34% in 2026.
- Per Business Quant data, the three most recent EBIT Margin figures were 609.34% in Q2 2026, 865.46% in Q1 2026, and 526.49% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Ocular Therapeutix | 2.40 Bn | 2.40 Bn | 11.46 Mn | -609.34% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -609.34% |
| Mar 31, 2026 | -865.46% |
| Dec 31, 2025 | -526.49% |
| Sep 30, 2025 | -472.35% |
| Jun 30, 2025 | -502.57% |
| Mar 31, 2025 | -597.47% |
| Dec 31, 2024 | -296.08% |
| Sep 30, 2024 | -298.20% |
| Jun 30, 2024 | -265.13% |
| Mar 31, 2024 | -214.00% |
| Dec 31, 2023 | -135.46% |
| Sep 30, 2023 | -127.41% |
| Jun 30, 2023 | -135.45% |
| Mar 31, 2023 | -168.60% |
| Dec 31, 2022 | -137.56% |
| Sep 30, 2022 | -180.06% |
| Jun 30, 2022 | -162.37% |
| Mar 31, 2022 | -135.23% |
| Dec 31, 2021 | -146.64% |
| Sep 30, 2021 | -160.69% |